Register an account to search through 14,000+ stocks! 

Ad

ZGNX – Zogenix Inc

Ad

✔ COMPLIANT

★★★

Pharmaceuticals | USA

Business: PASS

Zogenix Inc has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.

Financials: PASS

The financials pass all the three standards we check against.

FTSE

Debt/A22.94%
Cash/A12.44%
(AR+C)/A12.44%

AAOIFI

Debt/MC10.15%
Cash/MC27.21%

DJIM

Debt/24MC13.27%
Cash/24MC7.2%
AR/24MC%

Total Analysts: 9

Recommendation Rating

2.6

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 36.4

Low: 9

High: 62

Market cap1470912099
Assets651130000
Dividends per Share
Revenue Growth274

Zogenix, Inc. is a global biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for rare diseases. It is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The Company also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.

✔ FTSE✔ AAOIFI✔ DJIM

✔ COMPLIANT

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.

Ad

Responses